208 related articles for article (PubMed ID: 36104359)
21. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
22. Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck.
Park BJ; Mattox AK; Clayburgh D; Patel M; Bell RB; Yueh B; Leidner R; Xiao H; Couey M; Li S; Qin T; Sartor MA; Cairns B; MacDonough T; Halliwill K; Deschler D; Lin DT; Faquin WC; Sadow PM; Pai SI
Oral Oncol; 2022 Dec; 135():106183. PubMed ID: 36215771
[TBL] [Abstract][Full Text] [Related]
23. Free three-dimensional image software in local extension assessment of oral squamous cell carcinoma: a pilot study.
Gomes JPP; Costa ALF; Chone CT; Altemani AMAM; Altemani JMC; Lima CSP
Braz J Otorhinolaryngol; 2022; 88 Suppl 4(Suppl 4):S117-S123. PubMed ID: 36030174
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma.
Chen F; Qiu L; Mu Y; Sun S; Yuan Y; Shang P; Ji B; Wang Q
Front Surg; 2022; 9():893372. PubMed ID: 35983558
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Uppaluri R; Campbell KM; Egloff AM; Zolkind P; Skidmore ZL; Nussenbaum B; Paniello RC; Rich JT; Jackson R; Pipkorn P; Michel LS; Ley J; Oppelt P; Dunn GP; Barnell EK; Spies NC; Lin T; Li T; Mulder DT; Hanna Y; Cirlan I; Pugh TJ; Mudianto T; Riley R; Zhou L; Jo VY; Stachler MD; Hanna GJ; Kass J; Haddad R; Schoenfeld JD; Gjini E; Lako A; Thorstad W; Gay HA; Daly M; Rodig SJ; Hagemann IS; Kallogjeri D; Piccirillo JF; Chernock RD; Griffith M; Griffith OL; Adkins DR
Clin Cancer Res; 2020 Oct; 26(19):5140-5152. PubMed ID: 32665297
[TBL] [Abstract][Full Text] [Related]
26. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
[TBL] [Abstract][Full Text] [Related]
27. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial.
Lin JX; Tang YH; Zheng HL; Ye K; Cai JC; Cai LS; Lin W; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Zheng CH; Li P; Huang CM
Nat Commun; 2024 Jan; 15(1):41. PubMed ID: 38167806
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis.
Xiao W; Yuan Y; Wang S; Liao Z; Cai P; Chen B; Zhang R; Wang F; Zeng Z; Gao Y
Front Immunol; 2021; 12():798451. PubMed ID: 35095878
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial.
Yang B; Guo X; Le C; Su W; Li X; Zhang Y; Yang G; Liang W; Zheng Z; Wu J; Zhang Y; Hao A
Biomed Res Int; 2022; 2022():4727407. PubMed ID: 35898681
[TBL] [Abstract][Full Text] [Related]
32. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
[TBL] [Abstract][Full Text] [Related]
34. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
[TBL] [Abstract][Full Text] [Related]
35. Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma.
Blatt S; Krüger M; Rump C; Zimmer S; Sagheb K; Künzel J
PLoS One; 2022; 17(5):e0269136. PubMed ID: 35622885
[TBL] [Abstract][Full Text] [Related]
36. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.
Liu L; Liu Y; Gong L; Zhang M; Wu W
Cancer Biol Ther; 2020 Nov; 21(11):983-989. PubMed ID: 33092443
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of neoadjuvant chemotherapy as compared to upfront surgery for the management of oral squamous cell carcinoma: a systematic review and meta-analysis.
Kende P; Mathur Y; Varte V; Tayal S; Patyal N; Landge J
Int J Oral Maxillofac Surg; 2024 Jan; 53(1):1-10. PubMed ID: 37088590
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases.
Li X; Xia C; Liu M; Liu J; Dong M; Zhao H; Xu S; Wang D; Wei S; Song Z; Chen G; Liu H; Chen J
Front Oncol; 2022; 12():843116. PubMed ID: 36176413
[TBL] [Abstract][Full Text] [Related]
39. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
Liu J; Yang Y; Liu Z; Fu X; Cai X; Li H; Zhu L; Shen Y; Zhang H; Sun Y; Chen H; Yu B; Zhang R; Shao J; Zhang M; Li Z
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338088
[TBL] [Abstract][Full Text] [Related]
40. Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
Hirshoren N; Al-Kharouf I; Weinberger JM; Eliashar R; Popovtzer A; Knaanie A; Fellig Y; Neuman T; Meir K; Maly A; Vainer GW
Oncology; 2021; 99(7):464-470. PubMed ID: 33789303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
